Cargando…

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

OBJECTIVE: Fluzoparib (SHR3162) is a novel, potent poly(ADP-ribose) polymerases (PARP)1, 2 inhibitor that showed anti-tumor activity in xenograft models. We conducted a phase I, first-in-human, dose-escalation and expansion (D-Esc and D-Ex) trial in patients with advanced solid cancer. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Huiping, Liu, Rongrui, Shao, Bin, Ran, Ran, Song, Guohong, Wang, Ke, Shi, Yehui, Liu, Jihong, Hu, Wenjing, Chen, Fu, Liu, Xiaoran, Zhang, Gairong, Zhao, Chuanhua, Jia, Ru, Wang, Quanren, Rugo, Hope S., Zhang, Yifan, Li, Guangze, Xu, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369176/ https://www.ncbi.nlm.nih.gov/pubmed/32694901 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.08

Ejemplares similares

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
por: Zhu, Linggang, et al.
Publicado: (2020)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

3162 Colonization of Pregnant Women with Group B streptococcus in Latin America and Infant Outcomes
por: HogenEsch, Elena, et al.
Publicado: (2019)

Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
por: Wang, Lei, et al.
Publicado: (2019)

MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin
por: Fang, Chao, et al.
Publicado: (2016)

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
por: Long, Fei, et al.
Publicado: (2019)

Correction: MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin
Publicado: (2016)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation
por: Sun, Xin, et al.
Publicado: (2022)

A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy
por: Ji, Shoujian, et al.
Publicado: (2023)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
por: Deng, Ting, et al.
Publicado: (2023)

GEA 3162, a peroxynitrite donor, induces Bcl-2-sensitive, p53-independent apoptosis in murine bone marrow cells
por: Taylor, Emma L., et al.
Publicado: (2007)

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study
por: Zhang, Ruyan, et al.
Publicado: (2021)

DNA in serum extracellular vesicles is stable under different storage conditions
por: Jin, Yang, et al.
Publicado: (2016)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023)

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016)

Spatial Memory in Spontaneously Hypertensive Rats (SHR)
por: Sontag, Thomas-A., et al.
Publicado: (2013)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Cardioprotective Regimen of Adaptation to Chronic Hypoxia Diversely Alters Myocardial Gene Expression in SHR and SHR-mt(BN) Conplastic Rat Strains
por: Nedvedova, Iveta, et al.
Publicado: (2019)

Vasorelaxant and Hypotensive Effects of Cheonwangbosimdan in SD and SHR Rats
por: Kim, Bumjung, et al.
Publicado: (2018)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)
por: Li, Deyu, et al.
Publicado: (2023)

Antioxidant resveratrol restores renal sodium transport regulation in SHR
por: Javkhedkar, Apurva A, et al.
Publicado: (2015)

Quantification of platelets obtained by different centrifugation protocols in SHR rats()
por: Yazigi Junior, João Alberto, et al.
Publicado: (2015)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

The surface protein Shr of Streptococcus pyogenes binds heme and transfers it to the streptococcal heme-binding protein Shp
por: Zhu, Hui, et al.
Publicado: (2008)

Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)

Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective
por: Wang, Ran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l1qo89q1dtu5arevs8k292ltkp